Clinical trials in PubMed

In PubMed we found the present state of clinical trials related to FSHD from all over the world.

  1. Recruiting
    Effects of NMES on Muscle Function of Patients With FSHD: a Double-blind Randomized Controled Clinical Trial
    Primary Disease Facioscapulohumeral Dystrophy (FSHD)
    Other: Current flow between sensory and motor threshold
    Device: Current intensity upper of motor threshold by Kneehab XP technology
    Montpellier University Hospital, Montpellier, France
  2. Recruiting
    Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD
    Facio-Scapulo-Humeral Dystrophy, FSHD2, FSHD1
    Dietary Supplement: Creatine Monohydrate, Dietary Supplement: Placebo
    The Royal Children's Hospital, Melbourne, Victoria, Australia
  3. Completed
    Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy
    Facioscapulohumeral Muscular Dystrophy(FSHD)
    Biological: ATYR1940, Biological: Placebo
    Stanford University, Stanford, California, United States
    University of Iowa Children's Hospital, Iowa City, Iowa, United States
    OSU Wexner Medical Center, Columbus, Ohio, United States (and 4 more...)
  4. Completed
    1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy
    FSHD - Facioscapulohumeral Muscular Dystrophy
    Other: MRI
    Neuromuscular Research Unit, Department of Neurology, Rigshospitalet, Copenhagen, Denmark
  5. Active, not recruiting
    Rasch-analysis of Clinical Severity in FSHD
    Facioscapulohumeral Muscular Dystrophy
    University of Kansas Medical Center, Kansas City, Kansas, United States
    University of Utah, Salt Lake City, Utah, United States
  6. Recruiting NEW
    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
    Facioscapulohumeral Muscular Dystrophy
    Diagnostic Test: FSHD-specific functional rating scale
    Device: Electrical Impedance Myography
    University of California Los Angeles, Los Angeles, California, United States
    University of Kansas Medical Center, Kansas City, Kansas, United States
    Kennedy Krieger Institute, Baltimore, Maryland, United States (and 3 more...)
  7. Completed
    High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy
    FSHD - Facioscapulohumeral Muscular Dystrophy
    Other: Supervised training
    Other: Unsupervised training
    Other: Optional training
    Other: Control
    Copenhagen Neuromuscular Center, department of Neurology, Rigshospitalet, Copenhagen, Denmark
  8. Recruiting
    Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
    Facioscapulohumeral Muscular Dystrophy
    Drug: ACE-083
    Drug: ACE-083 or placebo
    University of California Los Angeles Medical Center, United States
    University of California Davis Medical Center, Sacramento, California, United States
    University of Kansas Medical Center, Kansas City, Kansas, United States (and 12 more...)
  9. Recruiting
    Routine Health Care of Patients With FSHD
    Primary Disease Fascioscapulohumeral Dystrophy (FSHD)
    Other: Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.
    Montpellier University Hospital-Saint Eloi Hospital, Montpellier, Languedoc-Roussillon, France
  10. Recruiting
    Study of Testosterone and rHGH in FSHD
    Facioscapulohumeral Muscular Dystrophy
    Drug: Testosterone Enanthate
    Drug: Somatropin
    University of Rochester, Rochester, New York, United States
  11. Unknown 
    Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)
    Procedure: Taking of blood
    Dietary Supplement: needle biopsy of the vastus lateralis muscle
    Dietary Supplement: Vit C Vit E Zn Se
    Dietary Supplement: Placebo Vit E Placebo Vit C Zn Se
    Montpellier University Hospital- Saint Eloi Hospital, Montpellier, Languedoc-Roussillon, France
  12. Active, not recruiting
    Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD
    Facioscapulohumeral Muscular Dystrophy1a
    Other: No intervention, observational
    Copenhagen Neuromuscular Center, Copenhagen, Denmark
  1. Completed
    Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular Dystrophy
    Biological: Placebo
    Biological: ATYR1940
    aTyr Pharma Investigative Site Rochester, New York, United States
    aTyr Pharma Investigative Site Columbus, Ohio, United States
    aTyr Pharma Investigative Site Marseille, France (and 2 more...)
  2. Completed
    A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD
    University of California – Davis, Sacramento, California, United States
    Children's National Medical Center, Washington, D.C., District of Columbia, United States
    University of Minnesota, Minneapolis, Minnesota, United States (and 9 more...)
  3. Recruiting
    Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
    Doris Leung, Baltimore, Maryland, United States
  4. Completed
    Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle andFacioscapulohumeral Muscular Dystrophy
    Limb Girdle Muscular Dystrophy
    Drug: ATYR1940
    University of California, Irvine, ALS and Neuromuscular Center Irvine, California, United States Stanford University, Stanford, California, United States
    University of Utah, Salt Lake City, Utah, United States (and 2 more...)
  5. Recruiting
    Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)
    Dystrophy
    Biological: Intramuscular injection
    Royan Institute, Tehran, Iran, Islamic Republic of
  6. Completed
    The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular Dystrophies
    Biological: ATYR1940
    Biological: Placebo
    University of California, Irvine, ALS and Neuromuscular Center Irvine, California, United States
    Kennedy Krieger Institute; The Johns Hopkins University School of Medicine Baltimore, Maryland, United States
    OSU Wexner Medical Center Columbus, Ohio, United States (and 3 more...)
  7. Active, not recruiting
    Bone Health in Facioscapulohumeral Muscular Dystrophy
    Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
    Concord Hospital Neurology Department, Hospital Road, Concord NSW 2139 Sydney, Australia
  8. Active, not recruiting
    Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension
    Biological: ATYR1940
    aTyr Pharma Investigative Site, Columbus, Ohio, United States
    aTyr Pharma Investigative Site, Rome, Italy
    aTyr Pharma Investigative Site, Nijmegen, Netherlands
  9. Recruiting
    Neurological and Psychiatric Comorbidities Patients With FSHD1 and 2
    Muscular Dystrophy, Facioscapulohumeral      Behavioral: Psychiatric test
    Hôpital Pasteur, Nice, France
  10. Unknown 
    Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2        Muscular Dystrophy, Facioscapulohumeral
    Biological: Blood test
    Hôpital Archet 1, Nice, France
  11. Completed
    Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy TypeFSHD Benefiting a Physical Training Introduced.
    Muscular Dystrophy Facioscapulohumeral
    Device: MRI
    Procedure: Biopsy
    CHU de Grenbole, Grenoble, France
    CHU de Saint-Etienne, St Etienne, France
  12. Completed
    Electrostimulation of Shoulder Girdle and Quadriceps Muscles inFacioscapulohumeral Muscular Dystrophy Patients
    Procedure: electrostimulation
    CHU de Nice, Nice, France
  1. Recruiting
    Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
    Myotonic Dystrophy Muscular Dystrophy (and 6 more...)
    University of Rochester Medical Center, Department of Neurology, Rochester, New York, United States
  2. Completed
    Protein Supplementation and Exercise in Patients With FSH Muscular Dystrophy- a Randomized Placebo Controlled Study
    Behavioral: Regular exercise
    Dietary Supplement: Protein-carbohydrate supplementation
    Neuromuscular Research Unit, Department of Neurology, Rigshospitalet, Copenhagen, Denmark
  3. Completed
    Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With FSHD : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.
    Other: FSHD training
    CHU de Grenbole, Grenoble, France
    CHU de Saint-Etienne, Saint-etienne, France
  4. Completed
    Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)
    Drug: Albuterol
    Drug: Oxandrolone
    Ohio State University Medical Center, Columbus, Ohio, United States
  5. Active, not recruiting
    Facioscapulohumeral Dystrophy in Children
    Neurological Observations, Pediatric Disorder Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
  6. Completed
    Study Evaluating MYO-029 in Adult Muscular Dystrophy
    Becker Muscular Dystrophy
    Limb-Girdle Muscular Dystrophy
    Drug: MYO-029
    Washington, District of Columbia, United States
    Kansas City, Kansas, United States
    Baltimore, Maryland, United States (and 6 more...)
  7. Completed
    Randomized Study of Albuterol in Patients WithFacioscapulohumeral Muscular Dystrophy
    Drug: albuterol
  8. Recruiting
    Molecular Analysis of Patients With Neuromuscular Disease
    Limb-girdle Muscular Dystrophy
    Duchenne Muscular Dystrophy
    Becker Muscular Dystrophy
    Children's Hospital Boston, Boston, Massachusetts, United States
  9. Completed
    Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy
    Myotonic Muscular Dystrophy
  10. Recruiting
    Acceptance and Commitment Therapy for Muscle Disease
    Muscle Diseases
    Behavioral: Acceptance and Commitment Therapy (ACT)
    King's College Hospital; The Royal London Hospital; University Hospital Southampton; King's College London, United Kingdom